Christina Coughlin Net Worth

The estimated Net Worth of Christina M. Coughlin is at least $1.58 Thousand dollars as of 22 April 2020. Christina Coughlin owns over 19,000 units of Rubius Therapeutics Inc stock worth over $1,577 and over the last 5 years he sold RUBY stock worth over $0. In addition, he makes $0 as Chief Medical Officer at Rubius Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Christina Coughlin RUBY stock SEC Form 4 insiders trading

Christina has made over 1 trades of the Rubius Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 19,000 units of RUBY stock worth $104,880 on 22 April 2020.

The largest trade he's ever made was buying 19,000 units of Rubius Therapeutics Inc stock on 22 April 2020 worth over $104,880. On average, Christina trades about 6,333 units every 0 days since 2020. As of 22 April 2020 he still owns at least 19,000 units of Rubius Therapeutics Inc stock.

You can see the complete history of Christina Coughlin stock trades at the bottom of the page.

Christina Coughlin biography

Dr. Christina M. Coughlin M.D., Ph.D. serves as Chief Medical Officer of the Company. Prior to joining our company, Dr. Coughlin served as chief medical officer of Tmunity Therapeutics, Inc., a clinical stage immunotherapy company, from July 2018 to November 2019. Prior to Tmunity, Dr. Coughlin served as chief medical officer at Immunocore Ltd. from April 2015 to July 2018. Earlier, she held positions at several pharmaceutical companies, including executive director of oncology clinical development at Novartis from December 2012 to April 2015. She holds an M.D. and Ph.D. from the University of Pennsylvania School of Medicine and a B.S. in mathematics and biology from Temple University.

How old is Christina Coughlin?

Christina Coughlin is 50, he's been the Chief Medical Officer of Rubius Therapeutics Inc since 2020. There are 12 older and 6 younger executives at Rubius Therapeutics Inc. The oldest executive at Rubius Therapeutics Inc is Michael Rosenblatt, 69, who is the Independent Director.

What's Christina Coughlin's mailing address?

Christina's mailing address filed with the SEC is C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE, MA, 02139.

Insiders trading at Rubius Therapeutics Inc

Over the last 6 years, insiders at Rubius Therapeutics Inc have traded over $2,165,279 worth of Rubius Therapeutics Inc stock and bought 305,000 units worth $6,624,680 . The most active insiders traders include Noubar Afeyan, Roger Pomerantz, and Robert Langer. On average, Rubius Therapeutics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $2,709. The most recent stock trade was executed by Dannielle Appelhans on 24 February 2023, trading 10,385 units of RUBY stock currently worth $1,350.

What does Rubius Therapeutics Inc do?

developing a novel enucleated cell (ecell)(tm) therapy platform for unmet medical needs. founded by flagship venturelabs.

Complete history of Christina Coughlin stock trades at Rubius Therapeutics Inc

Rubius Therapeutics Inc executives and stock owners

Rubius Therapeutics Inc executives and other stock owners filed with the SEC include:

• Pablo Cagnoni,
  President, Chief Executive Officer, Director
• Maiken Keson-Brookes,
  Chief Legal Officer, Corporate Secretary
• Dr. Pablo J. Cagnoni M.D., Ph.D.,
  CEO, Pres & Director
• David Epstein,
  Chairman of the Board
• Laurence A. Turka M.D.,
  Chief Scientific Officer and Head of Research & Translational Medicine
• Natalie Holles,
  Independent Director
• David R. Epstein B.Sc., M.B.A.,
  Exec. Chairman
• Dannielle Appelhans,
  Chief Operating Officer
• Anne Prener,
  Independent Director
• Jonathan Symonds,
  Independent Director
• Francis Cuss,
  Independent Director
• Catherine Sohn,
  Independent Director
• Noubar Afeyan,
  Independent Director
• Michael Rosenblatt,
  Independent Director
• Lori Melancon,
  IR Contact Officer
• Christina Coughlin,
  Chief Medical Officer
• Greg ..,
  Chief Quality Officer
• Laurence Turka,
  Chief Scientific Officer
• Kris Elverum,
  Senior Vice President - Business Development and Strategy
• Jose Carmona,
  Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer
• Jill Murray,
  VP & Head of HR
• Marissa Hanify,
  Director of Corp. Communications
• Maiken Keson-Brookes,
  Chief Legal Officer & Corp. Sec.
• Elhan Webb C.F.A.,
  VP of Investor Relations
• Mark J. Hernon,
  Chief Information Officer
• Spencer Fisk,
  Sr. VP & Chief Technical Operations Officer
• Jose I. Carmona,
  CFO, Principal Accounting Officer & Treasurer
• Ventures Fund Iv General Pa...,
  
• Susanne Schaffert,
  Director
• Robert Langer,
  Director
• Roger Pomerantz,
  Director
• Ventures Fund Iv General Pa...,
  
• Torben Straight Nissen,
  President
• Christopher L. Carpenter,
  Chief Medical Officer
• Dannielle Appelhans,
  CEO and President